Form 4: BioCryst Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

Director Theresa Heggie acquired 870 shares of BioCryst Pharmaceuticals common stock on May 31, 2024, in lieu of a portion of her quarterly board member retainer.

Summary

• On May 31, 2024, Theresa Heggie, a director of BioCryst Pharmaceuticals Inc., acquired 870 shares of common stock.
• The shares were issued in lieu of 50% of her quarterly cash Board Member retainer, amounting to $11,250.
• The price per share was $6.46.
• Following the transaction, Heggie directly owns 52,730 shares of BioCryst Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction of a director receiving shares as part of their compensation. It doesn't indicate any major positive or negative development for the company.

Positives

• The director's decision to take shares in lieu of cash may signal confidence in the company's future prospects.

Industry Context

This is a routine disclosure of insider transactions, which are common in publicly traded companies. Directors often receive compensation in the form of stock, aligning their interests with those of shareholders.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates